Application

Under the Paperwork Reduction Act of 1995 no persons are required to respond to a collection of information unless it displays a valid OMB control number. PTO Form 1478 (Rev 09/2006)

OMB No. 0651-0009 (Exp 02/28/2021)

---

Under the Paperwork Reduction Act of 1995 no persons are required to respond to a collection of information unless it displays a valid OMB control number. PTO Form 1478 (Rev 09/2006)

OMB No. 0651-0009 (Exp 02/28/2021)

Trademark/Service Mark Application, Principal Register

Serial Number: 88847647

Filing Date: 03/25/020

To the Commissioner for Trademarks:

MARK: PHASEBIO (stylized and/or with design, see mark)
The literal element of the mark consists of PHASEBIO. The applicant is not claiming color as a feature of the mark. The mark consists of Stylized letters "P" and "B," intersecting such that they resemble a heart design slightly skewed to the right, to the left of the word "PHASEBIO".
The applicant, PhaseBio Pharmaceuticals, Inc., a corporation of Delaware, having an address of
      1 Great Valley Parkway, Suite 30
      Malvern, Pennsylvania 19355
      United States
      tmclients@cooley.com

requests registration of the trademark/service mark identified above in the United States Patent and Trademark Office on the Principal Register established by the Act of July 5, 1946 (15 U.S.C. Section 1051 et seq.), as amended, for the following:

International Class 005:  Pharmaceutical preparations for treating heart disease, heart conditions, hypertension, pulmonary hypertension, and other disorders of the cardiopulmonary system; pharmaceutical preparations for treating orphan diseases, namely, cystic fibrosis, Duchenne muscular dystrophy, Becker muscular dystrophy, achondroplasia, short bowel syndrome, hypoparathyroidism, systemic lupus erythematosus, insulin-like growth factor deficiency, growth hormone deficiency; pharmaceuticals comprising drugs based on recombinant Elastin-like polypeptides technology platform, namely, pharmaceuticals for treating heart disease, heart conditions, hypertension, pulmonary hypertension, other disorders of the cardiopulmonary system, and orphan diseases, namely, cystic fibrosis, Duchenne muscular dystrophy, Becker muscular dystrophy, achondroplasia, short bowel syndrome, hypoparathyroidism, systemic lupus erythematosus, insulin-like growth factor deficiency, growth hormone deficiency; pharmaceutical preparations consisting of reversal agents for counteracting the effects of platelet aggregation inhibitors
Intent to Use: The applicant has a bona fide intention, and is entitled, to use the mark in commerce on or in connection with the identified goods/services.

International Class 042:  Medical and scientific research services, namely, medical research; medical and scientific research services all in the field of pharmaceuticals
Intent to Use: The applicant has a bona fide intention, and is entitled, to use the mark in commerce on or in connection with the identified goods/services.




The owner's/holder's proposed attorney information: Brendan J. Hughes. Other appointed attorneys are Salsabil Ahmed, Susan Piascik Christoff, John W. Crittenden, Brian Focarino, Bobby A. Ghajar, Colette A. Ghazarian, Rebecca Givner-Forbes, Katherine E. Green, Jeffrey H. Greene, Kelley B. Harrington, Shannan Higgins, Ariana G. Hiscott, Rose Mendenhall Kautz, Judd D. Lauter, Lori A. Levine, John Paul Oleksiuk, Anne H. Peck, Marcus D. Peterson, Dina Roumiantseva, Shane Rumbaugh, Jane van Benten, and Colleen Wellington-Caban. Brendan J. Hughes of Cooley LLP, is a member of the XX bar, admitted to the bar in XXXX, bar membership no. XXX, and the attorney(s) is located at
      1299 Pennsylvania Avenue, NW, Suite 700
      Washington, District of Columbia 20004
      United States
      trademarks@cooley.com
The docket/reference number is 309646-20000.
Brendan J. Hughes submitted the following statement: The attorney of record is an active member in good standing of the bar of the highest court of a U.S. state, the District of Columbia, or any U.S. Commonwealth or territory.

The applicant's current Correspondence Information:

Brendan J. Hughes

PRIMARY EMAIL FOR CORRESPONDENCE: trademarks@cooley.com       SECONDARY EMAIL ADDRESS(ES) (COURTESY COPIES): NOT PROVIDED Requirement for Email and Electronic Filing: I understand that a valid email address must be maintained by the applicant owner/holder and the applicant owner's/holder's attorney, if appointed, and that all official trademark correspondence must be submitted via the Trademark Electronic Application System (TEAS).

A fee payment in the amount of $550 has been submitted with the application, representing payment for 2 class(es).

Declaration

	Basis: If the applicant is filing the application based on use in commerce under 15 U.S.C. § 1051(a): The signatory believes that the applicant is the owner of the trademark/service mark sought to be registered; The mark is in use in commerce and was in use in commerce as of the filing date of the application on or in connection with the goods/services in the application; The specimen(s) shows the mark as used on or in connection with the goods/services in the application and was used on or in connection with the goods/services in the application as of the application filing date; and To the best of the signatory's knowledge and belief, the facts recited in the application are accurate. And/Or If the applicant is filing the application based on an intent to use the mark in commerce under 15 U.S.C. § 1051(b), § 1126(d), and/or § 1126(e): The signatory believes that the applicant is entitled to use the mark in commerce; The applicant has a bona fide intention to use the mark in commerce and had a bona fide intention to use the mark in commerce as of the application filing date on or in connection with the goods/services in the application; and To the best of the signatory's knowledge and belief, the facts recited in the application are accurate.
	To the best of the signatory's knowledge and belief, no other persons, except, if applicable, concurrent users, have the right to use the mark in commerce, either in the identical form or in such near resemblance as to be likely, when used on or in connection with the goods/services of such other persons, to cause confusion or mistake, or to deceive.
	To the best of the signatory's knowledge, information, and belief, formed after an inquiry reasonable under the circumstances, the allegations and other factual contentions made above have evidentiary support.
	The signatory being warned that willful false statements and the like are punishable by fine or imprisonment, or both, under 18 U.S.C. § 1001, and that such willful false statements and the like may jeopardize the validity of the application or submission or any registration resulting therefrom, declares that all statements made of his/her own knowledge are true and all statements made on information and belief are believed to be true.

Declaration Signature

Signature: /Jim Ballance/   Date: 03/25/2020
Signatory's Name: Ballance, David James
Signatory's Position: Vice President: Research & Scientific Affairs
Payment Sale Number: 88847647
Payment Accounting Date: 03/25/2020

Serial Number: 88847647
Internet Transmission Date: Wed Mar 25 17:19:34 ET 2020
TEAS Stamp: USPTO/BAS-XXX.XXX.XX.X-20200325171934040
227-88847647-7103262e7399c1bedf1c24c033f
9f28a92785bdf85771e49f9e93e2d1c78febe2b-
DA-19330397-20200325170207133995